Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Christophe Perrin"'
Autor:
Pierre Kubicek, Axel Le Cesne, Cyril Lervat, Maud Toulmonde, Christine Chevreau, Florence Duffaud, Louis-Romée Le Nail, Magali Morelle, Nathalie Gaspar, Cécile Vérité, Marie-Pierre Castex, Nicolas Penel, Esma Saada, Sylvain Causeret, François Bertucci, Christophe Perrin, Emmanuelle Bompas, Daniel Orbach, Valérie Laurence, Sophie Piperno-Neumann, Philippe Anract, Maria Rios, Jean-Claude Gentet, Éric Mascard, Stéphanie Pannier, Pascale Blouin, Sébastien Carrère, Loïc Chaigneau, Pauline Soibinet-Oudot, Nadège Corradini, Pascaline Boudou-Rouquette, Jean-Christophe Ruzic, Valérie Lebrun-Ly, Pascale Dubray-Longeras, Sharmini Varatharajah, Céleste Lebbe, Mickaël Ropars, Jean-Emmanuel Kurtz, Cécile Guillemet, Jean-Pierre Lotz, Juliane Berchoud, Grégory Cherrier, Françoise Ducimetière, Claire Chemin, Antoine Italiano, Charles Honoré, Emmanuel Desandes, Jean-Yves Blay, François Gouin, Perrine Marec-Bérard
Publikováno v:
BMC Cancer. 23
Background The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and you
Autor:
Mehdi Brahmi, Nathalie Gaspar, Justine Gantzer, Maud Toulmonde, Pascaline Boudou‐Rouquette, emmanuelle Bompas, Nelly Firmin, Thibaud Valentin, Mathilde Cancel, Florence Duffaud, Francois Bertucci, Christophe Perrin, Armelle Dufresne, Perrine Marec‐Bérard, Myriam Jean‐Denis, Isabelle Ray‐Coquard, Francois Le Loarer, Gaille Pierron, Franck Tirode, Jean‐Yves Blay, Sarah Watson
Publikováno v:
Cancer medicineREFERENCES.
CIC-rearranged sarcomas (CIC-RS) represent the most frequent subset of "Ewing-like" undifferentiated small round cell sarcomas. These tumors tend to be more aggressive than Ewing sarcomas. Moreover, treatment strategy can differ according to teams. T
Autor:
Loic Chaigneau, Mathilde Cancel, Corinne Delcambre, Corinne Bouvier, Emannuelle Bompas, Olivier Collard, Antoine Italiano, Christine Chevreau, Alice Hervieu, Pascaline Boudou-Rouquette, Vincent Vidal, Sylvie Chabaud, Olivier Mir, Esma Saada-Bouzid, Nicolas Penel, Maria Rios, Florence Duffaud, Camille Schiffler, Jean-Yves Blay, Christophe Perrin, Sophie Piperno-Neumann, Laure Monard, François Bertucci
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2021, 150, pp.108-118. ⟨10.1016/j.ejca.2021.03.039⟩
European Journal of Cancer, 2021, 150, pp.108-118. ⟨10.1016/j.ejca.2021.03.039⟩
Background This multi-cohort trial explored the efficacy and safety of regorafenib for patients with advanced sarcomas of bone origin; this report details the cohort of patients with metastatic or locally advanced chondrosarcoma (CS), progressing aft
Autor:
Lin Zhang, Yali Liu, Shanu Modi, Sara A. Hurvitz, Yeon Hee Park, Javad Shahidi, Cristina Saura, Junji Tsurutani, Seock-Ah Im, Hiroji Iwata, Yoshinori Ito, Ian E. Krop, Keun Seok Lee, Neelima Denduluri, Kenji Tamura, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Caleb Lee, José Baselga, Christophe Perrin, Sung Bae Kim, Kenjiro Aogi, Fabrice Andre, Javier Cortes, Antoine Yver
Publikováno v:
Cancer Research. 81:PD3-06
Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) is an open-label, international,
Autor:
Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin‐Broto, Antonio Lopez‐Pousa, Giovanni Grignani, Antonella Brunello, Jean‐Yves Blay, Oscar Tendero, Robert Diaz‐Beveridge, Virginia Ferraresi, Iwona Lugowska, Gabriele Infante, Luca Braglia, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Giuseppe Bianchi, Andrea Marrari, Carlo Morosi, Silvia Stacchiotti, Silvia Bagué, Jean Michel Coindre, Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Rosalba Miceli, Paolo Giovanni Casali, Alessandro Gronchi, Carla Dani, Chiara Villa, Antonella Messina, Lorella Rusi, Anna Maria Nuzzo, Carmen Nuzzo, Antonino De Paoli, Angela Buonadonna, Alessandro Comandone, Antonella Boglione, Lorenzo Livi, Daniela Greto, Nada Riva, Manuela Monti, Elisabetta Pennacchioli, Tommaso De Pas, Vincenzo Ippolito, Patrico Ledesma, Andres Redondo, Claudia Valverde, Raquel Bratos, Josefina Cruz, Javier Martinez Trufero, Ricardo Cubedo, Isabel Sevilla, Pablo Luna, Rafael Lopez, Pilar Sancho, Olivia Bally, Mehdi Brahmi, Isabelle Ray‐Coquard, Philippe Cassier, Nathalie Marques, Luis Tassy, Pascaline Boudou‐Rouquette, Camille Tlemsani, Jerome Alexandre, Francois Goldwasser, Emmanuelle Bompas, Frederic Rolland, Christophe Perrin, Marie Talarmin, Antoine Italiano, Maud Toulmonde, Mathieu Laramas, Jacques‐Olivier Bay, Pascale Dubray‐Longeras, Piotr Rutkowski
Publikováno v:
CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
[Background] The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfbb30d4e50e6a4c7aa1e8b68ac72933
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4293
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4293
Autor:
Javad Shahidi, Junji Tsurutani, Seock-Ah Im, Yeonhee Park, Shanu Modi, Caleb Lee, Hiroji Iwata, Kenji Tamura, Ian E. Krop, Sara A. Hurvitz, Antoine Yver, Christophe Perrin, Sung Bae Kim, Cristina Saura, Yoshinori Ito, Joohyuk Sohn, Eriko Tokunaga, Toshinari Yamashita, Lin Zhang, Javier Cortes, Neelima Denduluri, Fabrice Andre, Kenjiro Aogi, Keun Seok Lee, Shuquan Chen
Publikováno v:
N Engl J Med
The New England journal of medicine, vol 382, iss 7
The New England journal of medicine, vol 382, iss 7
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 do
Autor:
Fanny Le Du, Florence Godey, Thibault De La Motte Rouge, Christophe Perrin, Héloïse Bourien, Angélique Brunot, Julien Corné, Véronique Diéras, Véronique Quillien, Laurence Crouzet, C. Lefeuvre-Plesse, Lucie Robert
Publikováno v:
Scientific Reports
Scientific Reports, 2021, 11 (1), pp.17316. ⟨10.1038/s41598-021-96644-6⟩
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Nature Publishing Group, 2021, 11 (1), pp.17316. ⟨10.1038/s41598-021-96644-6⟩
Scientific Reports, 2021, 11 (1), pp.17316. ⟨10.1038/s41598-021-96644-6⟩
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Nature Publishing Group, 2021, 11 (1), pp.17316. ⟨10.1038/s41598-021-96644-6⟩
With the approval of new therapies targeting the PI3K pathway, the detection of PIK3CA mutations has become a key factor in treatment management for HR+/HER2− metastatic breast cancer (MBC). We developed multiplex digital PCR (dPCR) assays to detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d8e4b92387f4dde9f9978bf11bf184
https://hal.science/hal-03334040/file/s41598-021-96644-6.pdf
https://hal.science/hal-03334040/file/s41598-021-96644-6.pdf
Autor:
Elena Paillaud, Angéline Galvin, Marina Pulido, Christophe Perrin, Thomas Grellety, Pascaline Boudou-Rouquette, Diego Teyssonneau, Siavoshe Ayati, Arnaud Saint-Lezer, Stephane Culine, Mylene Annonay, Heidi Soulem-Laviec, Rabia Boulahssass, Capucine Baldini, Achille Tchalla, Pierre-Louis Soubeyran, Caroline Lalet, Soraya Mebarki, Lucas Hue, Simone Mathoulin-Pélissier
Publikováno v:
Journal of Clinical Oncology. 40:6541-6541
6541 Background: Health literacy (HL) is defined as the motivation and skills to access, understand, evaluate, and use information to make appropriate health decisions. The level of LS is low in Europe, including in France. For chronic patients, a lo
Autor:
Jérôme Blanchot, Vincent Lavoué, Angélique Brunot, Sophie Guillermet, Héloïse Bourien, Florence Godey, Thibault De La Motte Rouge, C. Lefeuvre-Plesse, Laurence Crouzet, Véronique Quillien, Boris Campillo-Gimenez, Véronique Diéras, Fanny Le Du, Christophe Perrin
Publikováno v:
The International journal of biological markers. 36(2)
Purpose: Genomic signatures, such as EndoPredict®, may help clinicians to decide which adjuvant treatment is the most appropriate. Methods: We propose the EndoPredict® assay for unclear cases of adjuvant treatment in patients treated in our compreh
Autor:
Eriko Tokunaga, Caleb Lee, Hiroji Iwata, Sara A. Hurvitz, Seock-Ah Im, Javier Cortes, Cristina Saura, Lin Zhang, Javad Shahidi, Kenjiro Aogi, Junji Tsurutani, Shanu Modi, Kenji Tamura, Antoine Yver, Ian E. Krop, Fabrice Andre, Christophe Perrin, Keun Seok Lee, Toshinari Yamashita, Shuquan Chen, Yeon Hee Park, Sung-Bae Kim, Neelima Denduluri, Yoshinori Ito, Joohyuk Sohn
Publikováno v:
Cancer Research. 80:GS1-03
Background [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody-drug conjugate with a HER2 antibody, peptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. In a phase 1 trial, the objective response rate (OR